Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  ResMed, Inc.    RMD

RESMED, INC.

(RMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ResMed : Morgans rates RMD as Add

11/02/2020 | 06:31pm EST

Resmed's first quarter was above Morgans expectations, underpinned by high single digit revenue growth and expanding gross margins, with lower operating expenses driving ongoing operating leverage.

The broker highlights ventilators continue to benefit from covid-19 demand, albeit slowing, driving an around 6% sales uplift and helping to overcome softness in the sleep business and SaaS.

A faster than expected recovery in patient diagnosis, ongoing strong masks resupply, and benign pricing environment, point to solid profitable growth, says the analyst- especially when coupled with pandemic-induced acceleration of macro trends.

Management continues to expect a 'U' shaped recovery through FY21, with covid-19 ventilator demand waning and sleep device headwinds, notes the broker. 

Morgans raises FY21-23 earnings estimates and increases the target to $30.99 from $29.33.

The Add rating is unchanged

Sector: Health Care Equipment & Services.

Target price is $30.99.Current Price is $27.47. Difference: $3.52 - (brackets indicate current price is over target). If RMD meets the Morgans target it will return approximately 11% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2020 Acquisdata Pty Ltd., source FN Arena

All news about RESMED, INC.
01/19INSIDER TRENDS : 90-Days of Insider Buying at ResMed Interrupted with Share Disp..
MT
01/13RESMED : 39th Annual J.P. Morgan Healthcare Conference
PU
01/12INSIDER TRENDS : 90-Day Insider Buying Trend at ResMed Slowed with Sale of Share..
MT
01/07RESMED : to Report Second Quarter Fiscal 2021 Earnings on January 28, 2021
BU
01/06RESMED : RMD) sees Significant Insider Sales Extending the Trend of Last Quarter
MT
01/05INSIDER TRENDS : ResMed Insider Disposition Slows 90-Days of Buys
MT
01/05INSIDER TRENDS : Insider Sale Scales Back 90-Day Buy Trend at ResMed
MT
01/05INSIDER TRENDS : ResMed Insider Disposition Interrupting 90-Day Buy Trend
MT
01/05RESMED : Announces Participation in the 39th Annual J.P. Morgan Healthcare Confe..
BU
2020RESMED : Zacks Investment Downgrades ResMed to Neutral From Outperform, Adjusts ..
MT
More news
Financials (USD)
Sales 2021 3 144 M - -
Net income 2021 692 M - -
Net Debt 2021 252 M - -
P/E ratio 2021 46,0x
Yield 2021 0,74%
Capitalization 31 232 M 31 232 M -
EV / Sales 2021 10,0x
EV / Sales 2022 9,15x
Nbr of Employees 7 770
Free-Float 77,0%
Chart RESMED, INC.
Duration : Period :
ResMed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESMED, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 191,14 $
Last Close Price 215,52 $
Spread / Highest target 11,8%
Spread / Average Target -11,3%
Spread / Lowest Target -36,0%
EPS Revisions
Managers and Directors
NameTitle
Michael J. Farrell Chief Executive Officer & Director
Robert Andrew Douglas President & Chief Operating Officer
Peter C. Farrell Non-Executive Chairman
Brett A. Sandercock Chief Financial Officer
Carlos M. Nunez Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
RESMED, INC.2.12%31 232
THERMO FISHER SCIENTIFIC10.00%203 954
DANAHER CORPORATION7.16%169 098
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.12.25%89 689
INTUITIVE SURGICAL, INC.-9.05%87 471
ILLUMINA, INC.9.80%59 313